600 200 800 200 means for controlling tumor associated ...€¦ · means for controlling tumor...

1
APL-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering a means for controlling tumor associated macrophages Elaine Liu 1 , Lan Yang 1 , Gavin Choy 2 , Xiaoling Zhang 2 , Tillman Pearce 2 , Mamatha Reddy 2 , Sanjeev Redkar 2 , Qian Shi 1 1 Zhejiang Apollomics Biotech Co., Ltd., Hangzhou, China, 2 Apollomics, Inc., Foster City, CA, USA Background APL-102 (previously CBT-102) is a multi-kinase inhibitor with a unique inhibitory profile. Previous presentation (Abstract #3945, AACR 2018) showed potent activity of APL-102 on VEGFR, BRAF, CRAF, key kinases in angiogenesis, MAPK pathways, and demonstrated in vivo efficacies in a broad spectrum of PDX models. The role of the tumor microenvironment (TME) in fostering the development of malignancies is prompting the pursuit of anticancer therapies that target its components as opposed to the tumor itself. As part of their immune surveillance duties, immune cells form part of this microenvironment, and yet, cancer cells have devised means to downplay their tumoricidal capabilities. Colony stimulating factor 1 receptor (CSF-1R) may offer such a means of controlling tumor associated macrophages in the tumor microenvironment. Materials and Methods The potency and selectivity of APL-102 against CSF1R kinase was evaluated in a cell free system where the enzyme activity was evaluated with Eurofins standard KinaseProfiler TM system. Cell growth inhibition was evaluated in the Ba/F3 hCSF1R cell line by the CellTiter- Glo (CTG) method. Engineered cell line Ba/F3 hCSF1R was treated with APL-102 and control compounds for 3 days at 37°C, 5% CO 2 and 95% humidity. The effect of APL-102 was further evaluated in murine myelogenous cell lines and human monocytes. Two murine cell lines M-NFS-60 and RAW264.7 were starved and then treated with APL-102 or comparator test articles for 3 days at 37°C, 5% CO 2 and 95% humidity. Human monocytes was isolated from PBMC and treated with APL-102 or control compounds for 5 days at 37°C, 5% CO 2 and 95% humidity. In vivo efficacy studies of APL-102 in combination with an anti-PD-1 antibody were performed in two immunotherapy sensitive syngeneic models, a subcutaneous MC-38 colon model in C57BL/6J mice and a CT-26 colon model in BALB/c mice. Treatment with APL-102 and anti- PD-1 antibody as single agent and in combination were initiated when tumors reached a mean volume of 100140 mm 3 . Tumor volumes were measured twice weekly in two dimensions using a caliper, and the volume was calculated using the formula: V = (L × W × W)/2. Tumor growth inhibition rate (TGI%) was used to evaluate the efficacy of in vivo studies. Results AACR Annual Meeting 2019, March 29 April 3, 2019, Atlanta, Georgia, USA Abstract No.: #2205 Synergistic effect of APL-102 combined with anti-PD-1 Figure 3: APL-102 demonstrated selective inhibition of the CSF-1 dependent M-NFS-60 cell line compared to CSF-1 independent RAW264.7 cell and human monocytes. In contrast, the three CSF1R targeting benchmark compounds GW2580, BLZ945, and PLX3397 showed highest inhibition of human monocyte. The results demonstrated that APL-102 inhibits CSF1R in a radiometric enzyme activity assay with an IC50 of 43 nM. APL-102 demonstrated growth inhibition in cells dependent on CSF1-CSF1R signaling. We demonstrated a mechanism of action for APL-102 anti-tumor activity, the inhibition of CSF1R-dependent tumor associated macrophages in TME in addition to targeting VEGFR-dependent angiogenesis and MAPK pathway. Combination of APL-102 and anti-PD-1 produced a more robust response than either single agent alone in syngeneic mouse models, which was associated with macrophage inhibition in TME. Rational combination with check-point inhibitors (CPIs) may improve the efficacy of APL-102 and broaden the efficacy of CPIs. Further studies may be needed to delineate the interplay among APL-102’s different mechanisms and its synergistic effects in combination with CPIs. Contact / Further Information Please visit Apollomics website at www.apollomicsinc.com for a PDF version of the poster presentation. APL-102 CSF1R Inhibition Cell line APL-102 GW2580 BLZ945 PLX3397 IC50 (μM) Max inh.(%) IC50 (μM) Max inh.(%) IC50 (μM) Max inh.(%) IC50 (μM) Max inh.(%) M-NFS-60 0.631 99.44% 1.145 99.02% 3.015 99.08% 0.348 99.32% RAW264.7 22.85 95.44% 4.056 81.91% >30 24.65% 16.36 95.16% Monocyte 6.98 96.05% 0.28 96.57% 0.20 96.34% 0.06 97.99% Figure 1: APL-102 inhibition of CSF1R enzyme activity was dose-dependent, with IC50 of 43 nM. The result was obtained with a radiometric enzymatic activity assay. Figure 2: In engineered Ba/F3 hCSF1R cell lines, the IC50 value of APL-102 was 0.588 μM compared to 1.333 μM of sulfatinib, a similar multi-kinase inhibitor, and 0.279 μM of GW2580, a more specific CSF1R kinase inhibitor. IC50 determination on M-NFS-60 0.001 0.01 0.1 1 10 100 0 50 100 150 200 200 400 600 800 CBT-102 GW2580 BLZ945 PLX3397 Conc. uM Surviving cells(%) IC50 determination on Monocyte 0.001 0.01 0.1 1 10 100 0 20 40 60 80 100 120 CBT-102 GW2580 BLZ945 PLX3397 Conc. uM Surviving cells(%) Summary IC50=43 nM Group Treatment Dose (mg/kg) TV (mm 3 ) Day 21 TGI (%) T/C (%) P value 1 Vehicle 0 1974.55±239.30 -- -- -- 2 APL-102 *10(5) 957.58±164.28 51.50 48.50 0.032 3 Anti-PD-1 antibody 10 1239.28±571.38 37.24 62.76 0.329 4 APL-102 *10(5) 479.07±144.00 75.74 24.26 0.001 Anti-PD-1 antibody 10 Figure 4: The efficacy study of APL-102 combined with an anti-PD-1 antibody in CT-26 colon cancer model. The results demonstrated effect in the combination of APL-102 with anti-PD-1 antibody. The TGI% was 75.74% in combination group, which was stronger than the single agent groups respectively. * : Groups 2 and 4 had changed doses from 10 to 5mpk during the experiment. Group Treatment Dose (mg/kg) TV (mm 3 ) Day 28 TGI (%) T/C (%) P value 1 Vehicle 0 2668.22±353.34 -- -- -- 2 APL-102 5 768.38±45.83 72.20 28.80 <0.001 3 APL-102 10 408.88±62.85 84.68 15.32 <0.001 4 Anti-PD-1 antibody 10 1180.07±190.60 55.77 44.23 0.003 5 APL-102 5 212.23±41.79 92.05 7.95 <0.001 Anti-PD-1 antibody 10 6 APL-102 10 263.34±42.43 90.13 9.87 <0.001 Anti-PD-1 antibody 10 Figure 5: Efficacy study of APL-102 combined with anti-PD-1 antibody in MC-38 colon cancer model. APL-102 showed significant inhibition on MC-38 tumor growth as a single agent. Anti-PD-1 antibody also showed inhibition as a single agent. The combination of APL-102 with anti-PD-1 antibody showed improved activity. Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 A. CD3 Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 B. CD4 Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 C. CD8 Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 D. F4/80 Figure 6: Expression of CD3, CD4, CD8, and F4/80 markers in tumor tissues tested by IHC in the MC-38 efficacy study. Group 1 was treated with vehicle, Group 2 was treated with 5 mg/kg of APL-102, Group 3 was treated with 10 mg/kg of APL-102, Group 4 was treated with 10 mg/kg of anti-PD-1 antibody, Group 5 was combined treatment with 5 mg/kg APL-102 and 10 mg/kg anti-PD-1 antibody, Group 6 was combined treatment with 10 mg/kg APL-102 and 10 mg/kg anti-PD-1 antibody. The results demonstrated that APL-102 increased the total T cells (CD3, Panel A), CD8 T cells (CD8, Panel C), but had minimal effect on CD4 T cells (CD4, Panel B). At the same time, APL-102 treatment significantly decreased macrophages in the tumor, both as single agent and in combination with an anti-PD-1 antibody. Vehicle APL-102 5 mpk APL-102 10 mpk aPD1 10 mpk APL-102+aPD1 5 mpk +10 mpk APL-102+aPD1 10 mpk+10 mpk APL-102 0 500 1000 1500 2000 2500 3000 3500 10 13 16 19 22 25 28 Tumor Volume (mm³) Treatment Days Efficacy study of APL-102 combined anti-PD-1 antibody in MC-38 colon cancer model Group 01, Vehicle, 0 mg/kg, QDx21days, p.o. Group 02, APL-102, 5 mg/kg, QDx21days, p.o. Group 03, APL-102, 10 mg/kg, QDx21days, p.o. Group 04, Anti-PD-1, 10 mg/kg, BIWx3weeks, i.p. Group 05, APL-102, 5 mg/kg, QDx21days, p.o., Anti-PD-1, 10 mg/kg, BIWx3weeks, i.p. Group 06, APL-102, 10 mg/kg, QDx21days, p.o., Anti-PD-1, 10 mg/kg, BIWx3weeks, i.p. APL-102 APL-102 IC50 determination on RAW264.7 0.001 0.01 0.1 1 10 100 0 50 100 150 200 250 CBT-102 GW2580 BLZ945 PLX3397 Conc. uM Surviving cells(%) APL-102 0 500 1000 1500 2000 2500 6 9 12 15 18 21 Tumor Volume (mm³) Treatment Days Efficacy study of APL-102 combined anti-PD-1 antibody in CT-26 colon cancer model Group 01, Vehicle, 0 mg/kg, QD*15days p.o. Group 02, APL-102, adjust 10 mg/kg, QD*6days, p.o. to 5 mg/kg, QD*9days since Day13 Group 03, anti-PD-1, 10 mg/kg, BIW*5times i.p. Group 04, APL-102, adjust 10 mg/kg, QD*6days, p.o. to 5 mg/kg, QD*9days since Day13anti-PD-1, 10 mg/kg, BIW*5times i.p.

Transcript of 600 200 800 200 means for controlling tumor associated ...€¦ · means for controlling tumor...

Page 1: 600 200 800 200 means for controlling tumor associated ...€¦ · means for controlling tumor associated macrophages Elaine Liu 1 , Lan Yang 1 , Gavin Choy 2 , Xiaoling Zhang 2 ,

APL-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering a

means for controlling tumor associated macrophagesElaine Liu1, Lan Yang1, Gavin Choy2, Xiaoling Zhang2, Tillman Pearce2, Mamatha Reddy2, Sanjeev Redkar2, Qian Shi1

1Zhejiang Apollomics Biotech Co., Ltd., Hangzhou, China, 2Apollomics, Inc., Foster City, CA, USA

Background

APL-102 (previously CBT-102) is a multi-kinase inhibitor with a unique inhibitory profile.

Previous presentation (Abstract #3945, AACR 2018) showed potent activity of APL-102 on

VEGFR, BRAF, CRAF, key kinases in angiogenesis, MAPK pathways, and demonstrated in

vivo efficacies in a broad spectrum of PDX models.

The role of the tumor microenvironment (TME) in fostering the development of malignancies is

prompting the pursuit of anticancer therapies that target its components as opposed to the tumor

itself. As part of their immune surveillance duties, immune cells form part of this

microenvironment, and yet, cancer cells have devised means to downplay their tumoricidal

capabilities. Colony stimulating factor 1 receptor (CSF-1R) may offer such a means of

controlling tumor associated macrophages in the tumor microenvironment.

Materials and Methods

The potency and selectivity of APL-102 against CSF1R kinase was evaluated in a cell free

system where the enzyme activity was evaluated with Eurofins standard KinaseProfilerTM

system. Cell growth inhibition was evaluated in the Ba/F3 hCSF1R cell line by the CellTiter-

Glo (CTG) method. Engineered cell line Ba/F3 hCSF1R was treated with APL-102 and control

compounds for 3 days at 37°C, 5% CO2 and 95% humidity.

The effect of APL-102 was further evaluated in murine myelogenous cell lines and human

monocytes. Two murine cell lines M-NFS-60 and RAW264.7 were starved and then treated with

APL-102 or comparator test articles for 3 days at 37°C, 5% CO2 and 95% humidity. Human

monocytes was isolated from PBMC and treated with APL-102 or control compounds for 5 days

at 37°C, 5% CO2 and 95% humidity.

In vivo efficacy studies of APL-102 in combination with an anti-PD-1 antibody were performed

in two immunotherapy sensitive syngeneic models, a subcutaneous MC-38 colon model in

C57BL/6J mice and a CT-26 colon model in BALB/c mice. Treatment with APL-102 and anti-

PD-1 antibody as single agent and in combination were initiated when tumors reached a mean

volume of 100-140 mm3. Tumor volumes were measured twice weekly in two dimensions

using a caliper, and the volume was calculated using the formula: V = (L × W × W)/2. Tumor

growth inhibition rate (TGI%) was used to evaluate the efficacy of in vivo studies.

Results

AACR Annual Meeting 2019, March 29 –April 3, 2019, Atlanta, Georgia, USA

Abstract No.: #2205

Synergistic effect of APL-102 combined with anti-PD-1

Figure 3: APL-102 demonstrated selective inhibition of the CSF-1 dependent M-NFS-60 cell line compared

to CSF-1 independent RAW264.7 cell and human monocytes. In contrast, the three CSF1R targeting

benchmark compounds GW2580, BLZ945, and PLX3397 showed highest inhibition of human monocyte.

The results demonstrated that APL-102 inhibits CSF1R in a radiometric enzyme activity assay with an IC50 of

43 nM. APL-102 demonstrated growth inhibition in cells dependent on CSF1-CSF1R signaling.

We demonstrated a mechanism of action for APL-102 anti-tumor activity, the inhibition of CSF1R-dependent

tumor associated macrophages in TME in addition to targeting VEGFR-dependent angiogenesis and MAPK

pathway. Combination of APL-102 and anti-PD-1 produced a more robust response than either single agent

alone in syngeneic mouse models, which was associated with macrophage inhibition in TME. Rational

combination with check-point inhibitors (CPIs) may improve the efficacy of APL-102 and broaden the efficacy

of CPIs. Further studies may be needed to delineate the interplay among APL-102’s different mechanisms and

its synergistic effects in combination with CPIs.

Contact / Further Information

Please visit Apollomics website at www.apollomicsinc.com for

a PDF version of the poster presentation.

APL-102 CSF1R Inhibition

Cell line

APL-102 GW2580 BLZ945 PLX3397

IC50 (μM) Max inh.(%) IC50 (μM) Max inh.(%) IC50 (μM) Max inh.(%) IC50 (μM) Max inh.(%)

M-NFS-60 0.631 99.44% 1.145 99.02% 3.015 99.08% 0.348 99.32%

RAW264.7 22.85 95.44% 4.056 81.91% >30 24.65% 16.36 95.16%

Monocyte 6.98 96.05% 0.28 96.57% 0.20 96.34% 0.06 97.99%

Figure 1: APL-102 inhibition of CSF1R

enzyme activity was dose-dependent, with

IC50 of 43 nM. The result was obtained with

a radiometric enzymatic activity assay.

Figure 2: In engineered Ba/F3 hCSF1R cell lines,

the IC50 value of APL-102 was 0.588 µM

compared to 1.333 µM of sulfatinib, a similar

multi-kinase inhibitor, and 0.279 µM of GW2580,

a more specific CSF1R kinase inhibitor.

IC50 determination on M-NFS-60

0.001 0.01 0.1 1 10 1000

50

100

150

200200

400

600

800CBT-102

GW2580

BLZ945

PLX3397

Conc. uM

Su

rviv

ing

cells(%

)

IC50 determination on Monocyte

0.001 0.01 0.1 1 10 1000

20

40

60

80

100

120CBT-102

GW2580

BLZ945

PLX3397

Conc. uM

Su

rviv

ing

cells(%

)

Summary

IC50=43 nM

Group TreatmentDose

(mg/kg)

TV (mm3)

Day 21TGI (%) T/C (%) P value

1 Vehicle 0 1974.55±239.30 -- -- --

2 APL-102 *10(5) 957.58±164.28 51.50 48.50 0.032

3Anti-PD-1

antibody10 1239.28±571.38 37.24 62.76 0.329

4

APL-102 *10(5)

479.07±144.00 75.74 24.26 0.001Anti-PD-1

antibody10

Figure 4: The efficacy study of APL-102 combined with an anti-PD-1 antibody in CT-26 colon cancer model.

The results demonstrated effect in the combination of APL-102 with anti-PD-1 antibody. The TGI% was

75.74% in combination group, which was stronger than the single agent groups respectively.

* : Groups 2 and 4 had changed doses from 10 to 5mpk during the experiment.

Group TreatmentDose

(mg/kg)

TV (mm3)

Day 28TGI (%) T/C (%) P value

1 Vehicle 0 2668.22±353.34 -- -- --

2 APL-102 5 768.38±45.83 72.20 28.80 <0.001

3 APL-102 10 408.88±62.85 84.68 15.32 <0.001

4Anti-PD-1

antibody10 1180.07±190.60 55.77 44.23 0.003

5

APL-102 5

212.23±41.79 92.05 7.95 <0.001Anti-PD-1

antibody10

6

APL-102 10

263.34±42.43 90.13 9.87 <0.001Anti-PD-1

antibody10

Figure 5: Efficacy study of APL-102 combined with anti-PD-1 antibody in MC-38 colon cancer model.

APL-102 showed significant inhibition on MC-38 tumor growth as a single agent. Anti-PD-1 antibody also

showed inhibition as a single agent. The combination of APL-102 with anti-PD-1 antibody showed improved

activity.

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6A.

CD3

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6B.

CD4

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6C.

CD8

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6D.

F4/80

Figure 6: Expression of CD3, CD4, CD8, and F4/80 markers in tumor tissues tested by IHC in the MC-38

efficacy study. Group 1 was treated with vehicle, Group 2 was treated with 5 mg/kg of APL-102, Group 3 was

treated with 10 mg/kg of APL-102, Group 4 was treated with 10 mg/kg of anti-PD-1 antibody, Group 5 was

combined treatment with 5 mg/kg APL-102 and 10 mg/kg anti-PD-1 antibody, Group 6 was combined

treatment with 10 mg/kg APL-102 and 10 mg/kg anti-PD-1 antibody. The results demonstrated that APL-102

increased the total T cells (CD3, Panel A), CD8 T cells (CD8, Panel C), but had minimal effect on CD4 T

cells (CD4, Panel B). At the same time, APL-102 treatment significantly decreased macrophages in the tumor,

both as single agent and in combination with an anti-PD-1 antibody.

VehicleAPL-102

5 mpk

APL-102

10 mpk

aPD1

10 mpk

APL-102+aPD1

5 mpk +10 mpk

APL-102+aPD1

10 mpk+10 mpk

APL-102

0

500

1000

1500

2000

2500

3000

3500

10 13 16 19 22 25 28

Tum

or

Vo

lum

e (

mm

³)

Treatment Days

Efficacy study of APL-102 combined anti-PD-1 antibody in

MC-38 colon cancer model

Group 01, Vehicle, 0 mg/kg, QDx21days, p.o.

Group 02, APL-102, 5 mg/kg, QDx21days, p.o.

Group 03, APL-102, 10 mg/kg, QDx21days, p.o.

Group 04, Anti-PD-1, 10 mg/kg, BIWx3weeks, i.p.

Group 05, APL-102, 5 mg/kg, QDx21days, p.o., Anti-PD-1,

10 mg/kg, BIWx3weeks, i.p.

Group 06, APL-102, 10 mg/kg, QDx21days, p.o., Anti-PD-1,

10 mg/kg, BIWx3weeks, i.p.

APL-102 APL-102

IC50 determination on RAW264.7

0.001 0.01 0.1 1 10 1000

50

100

150

200

250CBT-102

GW2580

BLZ945

PLX3397

Conc. uM

Su

rviv

ing

cells(%

)

APL-102

0

500

1000

1500

2000

2500

6 9 12 15 18 21

Tum

or

Vo

lum

e (

mm

³)

Treatment Days

Efficacy study of APL-102 combined anti-PD-1 antibody in

CT-26 colon cancer model

Group 01, Vehicle, 0 mg/kg, QD*15days p.o.

Group 02, APL-102, adjust 10 mg/kg, QD*6days, p.o. to 5 mg/kg,

QD*9days since Day13Group 03, anti-PD-1, 10 mg/kg, BIW*5times i.p.

Group 04, APL-102, adjust 10 mg/kg, QD*6days, p.o. to 5 mg/kg,

QD*9days since Day13; anti-PD-1, 10 mg/kg, BIW*5times i.p.